Ipsen Biopharma

INCRELEX

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Ipsen Biopharma

Increlex HCPCS:

J2170

HCPCS Code Descriptor:

Injection, mecasermin, 1 mg

Category:

J Code

Increlex NDCs:

15054-1040-05

Primary Type:

Growth Disorder

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Subcutaneous

Increlex CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have identified listing errors with the following NDCs:

15054-1040-05

About Increlex:

INCRELEX is a Growth Disorder drug manufactured by Ipsen Biopharma and administered via the Subcutaneous route of administration. The J Code: J2170 is aligned to the drug INCRELEX.

Increlex is a medication used to treat growth delay in children who lack a certain insulin-like growth factor in their bodies called IGF-1. Increlex is a man-made form of IGF-1. IGF-1 is crucial for the growth of bones and muscles. Increlex is thought to work by replacing IGF-1 in children whose bodies do not naturally produce enough, encouraging normal growth.

ACCESS PRICING AND MORE BY REGISTERING

J2170 Added Date:

January 1, 2007

J2170 Effective Date:

January 1, 2007

J2170 Termination Date:

HCPCS Active

Increlex billing and coding information can be found through Ipsen Biopharma at the link below:
Increlex patient assistance information can be found through Ipsen Cares at the URL: http://www.ipsencares.com/
INCRELEX prescribing information can be found at the link below:
Information regarding INCRELEX’s side effects can be found at MedlinePlus